- Conditions
- Chronic Hepatitis C
- Interventions
- valopicitabine, pegylated interferon, ribavirin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 366
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Pegylated-interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF/VEL, SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 50
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 35 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
- Conditions
- HIV Infections
- Interventions
- Ribavirin, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Anaheim, California • Coronado, California • San Jose, California + 7 more
- Conditions
- Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
- Interventions
- Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment, Off-site HCV evaluation and treatment
- Drug · Behavioral
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Syracuse, New York
- Conditions
- Healthy Volunteer
- Interventions
- ribavirin [Copegus]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Chronic Hepatitis C
- Interventions
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Sofosbuvir, GS-5816
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
- Conditions
- Hepatitis C
- Interventions
- VX-950, ribavirin, peginterferon alfa-2a
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Hepatitis C Infection, Genotype 1
- Interventions
- recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • National City, California • Miami, Florida + 3 more
- Conditions
- End-Stage Renal Disease, Hepatitis C
- Interventions
- Zepatier, Ribavirin, Sofosbuvir
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- Sofosbuvir, Ledipasvir, GS-9669, GS-9451
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
- Conditions
- Hepatitis C
- Interventions
- Infliximab, Placebo
- Drug
- Lead sponsor
- Nizar Zein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Port Orange, Florida • Louisville, Kentucky + 3 more
- Conditions
- HIV-1 Infection, Hepatitis
- Interventions
- Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
- Conditions
- Hepatitis C
- Interventions
- Interferon-alpha
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 21 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Atlanta, Georgia
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- La Jolla, California • Sacramento, California • Orlando, Florida + 14 more